Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinumand paclitaxel-based chemotherapy?
A. Gadducci1,*, M. Notarnicola1, A. Menichetti1, N. Lanfredini1, A. Fanucchi1, S. Cosio1
1 Department of Experimental and Clinical Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy
Eur. J. Gynaecol. Oncol. 2016, 37(2), 182–188; https://doi.org/10.12892/ejgo2763.2016
Published: 10 April 2016
Purpose of investigation: To correlate serum CA125 at relapse with survival in ovarian cancer patients who achieved a complete response after primary cytoreduction and paclitaxel- and platinum-based chemotherapy. Materials and Methods: The study was conducted in 104 patients. Results: The 25%, 50%, and 75% quantiles of CA125 levels at relapse were 46, 118, and 190 U/ml. By log-rank test, survival after recurrence was related to consolidation treatment (p = 0.046), platinum-free interval (PFI) (p < 0.000005), number of recurrence sites (p = 0.03), treatment at recurrence (p = 0.002), and serum CA125 taking 118 U/ml as cut-off (p = 0.013). On multivariate analysis, consolidation treatment (p = 0.007), PFI (p = 0.0001), treatment at recurrence (p = 0.01), and serum CA125 taking 118 U/ml as cut-off (p =0.04) were independent prognostic variables for survival. Conclusions: Serum CA125 at relapse was an independent prognostic variable. Patients with serum CA125 >118 U/m had 1.943 higher risk of death than those with lower antigen value.
Secondary cytoreductive surgery
Survival after recurrence